Literature DB >> 25592451

Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency.

Luisa Spadaro1, Davide Noto, Graziella Privitera, Tania Tomaselli, Giuseppe Fede, Roberto Scicali, Salvatore Piro, Francesca Fayer, Ida Altieri, Maurizio Averna, Francesco Purrello.   

Abstract

BACKGROUNDS AND AIMS: Adrenal insufficiency (AI) has been reported in patients with stable cirrhosis. A lack of substrates has been suggested as a possible contributing pathogenic mechanism leading to glucocorticoid deficiency in these subjects. To better explore this hypothesis, we studied lipoproteins in cirrhotics with and without AI.
METHODS: A total of 81 cirrhotic patients and 30 normal volunteers were enrolled. The severity of liver disease was graded by Child-Pugh score. Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), and apolipoprotein AI (Apo-AI) levels were evaluated. HDL subfractions were measured by gradient gel electrophoresis. Adrenal function was assessed by the Low-Dose Short Synacthen Test.
RESULTS: Cirrhotic patients showed a significant reduction of TC, HDL, LDL, TG, and Apo-AI levels compared with controls. HDL3 was significantly lower, while HDL2 was higher, in cirrhotics compared with the controls. AI was observed in 26 patients. TC, TG, HDL, and Apo-AI were significantly reduced in cirrhotics with AI compared with those with normal adrenal function. HDL2 and HDL3 did not differ between these two groups. Delta cortisol was related to TC (r = 0.30, p < 0.01), TG (r = 0.22, p = 0.05), and Apo-AI (r = 0.37, p < 0.001). Multivariate analysis revealed that Apo-AI and HDL were independently associated with AI.
CONCLUSION: Our study shows that TC, TG, HDL, and Apo-AI are reduced in cirrhotics with AI. In particular, because both HDL and Apo-AI play a primary role in providing substrates for steroidogenesis to adrenal cells, this deficiency may contribute to the pathogenesis of AI in these patients.

Entities:  

Keywords:  HDL cholesterol; adrenal insufficiency; apolipoprotein AI; cirrhosis

Mesh:

Substances:

Year:  2015        PMID: 25592451     DOI: 10.3109/00365521.2014.985707

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

Review 1.  Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.

Authors:  Gaetano Bertino; Graziella Privitera; Francesco Purrello; Shirin Demma; Emanuele Crisafulli; Luisa Spadaro; Nikolaos Koukias; Emmanuel A Tsochatzis
Journal:  Intern Emerg Med       Date:  2016-06-07       Impact factor: 3.397

Review 2.  Abnormalities of Lipoprotein Levels in Liver Cirrhosis: Clinical Relevance.

Authors:  Graziella Privitera; Luisa Spadaro; Simona Marchisello; Giuseppe Fede; Francesco Purrello
Journal:  Dig Dis Sci       Date:  2017-11-25       Impact factor: 3.199

3.  An unusual cause of anemia in cirrhosis: spur cell anemia, a case report with review of literature.

Authors:  Graziella Privitera; Giovanni Meli
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2016

4.  Clinical characteristics and prevalence of adrenal insufficiency in hemodynamically stable patients with cirrhosis.

Authors:  Sang Hoon Park; Min Sun Joo; Byoung Hoon Kim; Ha Na Yoo; Sung Eun Kim; Jin Bae Kim; Myoung Kuk Jang; Dong Jun Kim; Myung Seok Lee
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

5.  Predictive Factors of Adrenal Insufficiency in Outpatients with Indeterminate Serum Cortisol Levels: A Retrospective Study.

Authors:  Worapaka Manosroi; Mattabhorn Phimphilai; Jiraporn Khorana; Pichitchai Atthakomol; Tanyong Pipanmekaporn
Journal:  Medicina (Kaunas)       Date:  2020-01-08       Impact factor: 2.430

6.  Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism.

Authors:  Yanyong Xu; Yuanyuan Li; Kavita Jadhav; Xiaoli Pan; Yingdong Zhu; Shuwei Hu; Shaoru Chen; Liuying Chen; Yong Tang; Helen H Wang; Ling Yang; David Q-H Wang; Liya Yin; Yanqiao Zhang
Journal:  Nat Metab       Date:  2021-01-18

7.  Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation.

Authors:  Roberto Scicali; Antonino Di Pino; Chiara Pavanello; Alice Ossoli; Arianna Strazzella; Antonia Alberti; Stefania Di Mauro; Alessandra Scamporrino; Francesca Urbano; Agnese Filippello; Salvatore Piro; Agata Maria Rabuazzo; Laura Calabresi; Francesco Purrello
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

8.  Analysis of Arterial Stiffness and Sexual Function after Adding on PCSK9 Inhibitor Treatment in Male Patients with Familial Hypercholesterolemia: A Single Lipid Center Real-World Experience.

Authors:  Roberto Scicali; Giorgio Ivan Russo; Marina Di Mauro; Flavia Manuele; Grazia Di Marco; Antonino Di Pino; Viviana Ferrara; Agata Maria Rabuazzo; Salvatore Piro; Giuseppe Morgia; Francesco Purrello
Journal:  J Clin Med       Date:  2020-11-08       Impact factor: 4.241

9.  A Predictive Risk Score to Diagnose Adrenal Insufficiency in Outpatients: A 7 Year Retrospective Cohort Study.

Authors:  Worapaka Manosroi; Tanyong Pipanmekaporn; Jiraporn Khorana; Pichitchai Atthakomol; Mattabhorn Phimphilai
Journal:  Medicines (Basel)       Date:  2021-03-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.